Evidence map›Paper›PMID 27565972›Full record

Observational studyJournal of bone and mineral metabolism2017

Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice.

Satoshi Soen, Takashi Umemura, Tsuyoshi Ando, Toshiaki Kamisaki, Masahiko Nishikawa, Ryoichi Muraoka, Yoshinori Ikeda, Kyoko Takeda, Mitsuharu Osawa, Toshitaka Nakamura

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of bone and mineral metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Satoshi SoenDepartment of Orthopaedic Surgery and Rheumatology, Nara Hospital, Kindai University Faculty of Medicine, 1248-1 Otodacho, Ikoma, Nara, 630-0293, Japan.
Takashi UmemuraPost-marketing Medical Research Department, Ajinomoto Pharmaceuticals Co., Ltd., 1-1 Irifune 2-Chome, Chuo-ku, Tokyo, 104-0042, Japan. takashi_umemura@eapharma.co.jp.
Tsuyoshi AndoPost-marketing Medical Research Department, Ajinomoto Pharmaceuticals Co., Ltd., 1-1 Irifune 2-Chome, Chuo-ku, Tokyo, 104-0042, Japan.
Toshiaki KamisakiPost-marketing Medical Research Department, Ajinomoto Pharmaceuticals Co., Ltd., 1-1 Irifune 2-Chome, Chuo-ku, Tokyo, 104-0042, Japan.
Masahiko NishikawaPost-marketing Medical Research Department, Ajinomoto Pharmaceuticals Co., Ltd., 1-1 Irifune 2-Chome, Chuo-ku, Tokyo, 104-0042, Japan.
Ryoichi MuraokaData Science Group, Clinical Development Department, Ajinomoto Pharmaceuticals Co., Ltd., 1-1 Irifune 2-Chome, Chuo-ku, Tokyo, 104-0042, Japan.
Yoshinori IkedaPost-marketing Surveillance Group, Pharmacovigilance Department, Japan Development Center, Takeda Pharmaceutical Co., Ltd., 1-1 Doshomachi 4-Chome, Chuo-ku, Osaka, 540-8645, Japan.
Kyoko TakedaPost-marketing Surveillance Group, Pharmacovigilance Department, Japan Development Center, Takeda Pharmaceutical Co., Ltd., 1-1 Doshomachi 4-Chome, Chuo-ku, Osaka, 540-8645, Japan.
Mitsuharu OsawaDrug Fostering and Evolution Coordination Department, Corporate Medical Affairs, Eisai Co., Ltd., 6-10 Koishikawa 4-Chome, Bunkyo-ku, Tokyo, 112-8088, Japan.
Toshitaka NakamuraNational Center for Global Health and Medicine, 21-1 Toyama 1-Chome, Shinjuku-ku, Tokyo, 162-8655, Japan.
Ajinomoto (Japan) · JPTakeda (Japan) · JPEisai (Japan) · JPKindai University · JPNational Center for Global Health and Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, the only available evidence for the efficacy of once-weekly 17.5 mg risedronate in preventing vertebral fractures was obtained in a 48-week study in Japan. We performed a 156-week prospective, longitudinal, observational study to determine the efficacy of the 17.5 mg risedronate in preventing vertebral fractures. We included Japanese patients with established osteoporosis who were older than 50 years and had radiographically confirmed vertebral fractures. The primary endpoint was the incidence of vertebral fractures every 24 weeks, with the final interval spanning 36 weeks. We also calculated the change in bone mineral density of the lumbar spine (L

Indexed as

Asian PeopleAgedBone DensityBone Density Conservation AgentsCollagen Type IDrug Administration ScheduleFemaleHip FracturesHumansIncidenceJapanLongitudinal StudiesLumbar VertebraeMaleOsteoporosisPatient ComplianceBone Density Conservation AgentsCollagen Type Icollagen type I trimeric cross-linked peptidePeptidesRisedronic AcidEstablished osteoporosisLumbar bone mineral densityObservational studyOnce-weekly risedronateRisk of vertebral fracture

Identifiers

PMID27565972
OpenAlexW2509692501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.